{"id":"W4321606338","doi":"10.1016/s2213-2600(22)00504-5","title":"Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","year":2023,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Center for Advancing Translational Sciences; NIHR Leicester Clinical Research Facility; National Institute for Health and Care Research; National Institutes of Health; Vertex Pharmaceuticals; Medical Research Council; Cystic Fibrosis Foundation Therapeutics; Mylan; Cystic Fibrosis Foundation","keywords":"Ivacaftor; Cystic fibrosis; Medicine; Cystic fibrosis transmembrane conductance regulator; Internal medicine; Clinical endpoint; Randomized controlled trial; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01028207,0.0004816036,0.003893076,0.0006453975,0.000146448,0.0000199398,0.0004092003,0.0001684584,0.0002461973],"category_scores_gemma":[0.01000428,0.0002431477,0.0001873177,0.001500405,0.001134,0.0001448948,0.0001295134,0.0006981068,0.00003137756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001209613,"about_ca_system_score_gemma":0.0003361348,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009069686,"about_ca_topic_score_gemma":0.00002194408,"domain_scores_codex":[0.9941363,0.001102204,0.001927136,0.0006579485,0.001307701,0.0008687653],"domain_scores_gemma":[0.9890369,0.008542377,0.0006874601,0.001031328,0.0002899779,0.0004119602],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9618864,0.0002747619,0.001634218,0.000907943,0.0003907222,0.0001903929,0.000461946,0.00007855645,0.02306411,0.0002718829,0.003786601,0.007052488],"study_design_scores_gemma":[0.9442501,0.00528423,0.01612085,0.004715108,0.0005634074,0.00004075895,0.000772259,0.0003864739,0.001786284,0.00005814254,0.02573479,0.0002875855],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.976367,0.01073416,0.0001410862,0.003866855,0.0001051729,0.007228765,0.00007631083,0.000177841,0.001302817],"genre_scores_gemma":[0.9946318,0.001542346,0.0001938029,0.0005812219,0.001957085,0.0006121976,0.00007409567,0.000076387,0.0003311205],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02194819,"threshold_uncertainty_score":0.9983349,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08485193142621349,"score_gpt":0.4004895064889591,"score_spread":0.3156375750627456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}